Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2022-07-08 4:57 pm Sale | 13G | SYROS PHARMACEUTICALS INC SYRS | BlackRock Inc. BLK | 1,524,309 2.4% | -2,707,959 (-63.98%) | View |
| 2022-04-11 09:01 am Sale | 13G | SYROS PHARMACEUTICALS INC SYRS | FMR LLC | 5,797,876 9.298% | -3,534,921 (-37.88%) | View |
| 2022-02-14 06:41 am Purchase | 13G | SYROS PHARMACEUTICALS INC SYRS | Bain Capital Life Sciences Fund II L.P. | 6,264,420 11% | 479,384 (+8.29%) | View |
| 2022-02-14 06:06 am Sale | 13G | SYROS PHARMACEUTICALS INC SYRS | Nikko Asset Management Americas Inc. | 0 0% | -4,381,992 (Position Closed) | View |
| 2022-02-11 4:17 pm Purchase | 13G | SYROS PHARMACEUTICALS INC SYRS | Ally Bridge MedAlpha Master Fund L.P. | 3,930,520 6.3% | 897,395 (+29.59%) | View |
| 2022-02-11 06:28 am Purchase | 13G | SYROS PHARMACEUTICALS INC SYRS | Artal International S.C.A. | 3,500,000 5.6% | 3,500,000 (New Position) | View |
| 2022-02-09 10:01 am Purchase | 13G | SYROS PHARMACEUTICALS INC SYRS | FMR LLC | 9,332,797 14.999% | 2,420,462 (+35.02%) | View |
| 2022-02-04 06:09 am Sale | 13G | SYROS PHARMACEUTICALS INC SYRS | Sumitomo Mitsui Trust Holdings Inc. | 0 0% | -4,381,992 (Position Closed) | View |
| 2022-02-03 4:41 pm Purchase | 13G | SYROS PHARMACEUTICALS INC SYRS | BlackRock Inc. BLK | 4,232,268 6.8% | 906,708 (+27.26%) | View |
| 2021-03-10 3:12 pm Sale | 13G | SYROS PHARMACEUTICALS INC SYRS | ARK Investment Management LLC | 8,589,598 13.94% | -451,723 (-5.00%) | View |
| 2021-02-16 4:33 pm Sale | 13G | SYROS PHARMACEUTICALS INC SYRS | ARK Investment Management LLC | 9,041,321 19.74% | -2,171,185 (-19.36%) | View |
| 2021-02-16 3:12 pm Sale | 13G | SYROS PHARMACEUTICALS INC SYRS | Point72 Asset Management L.P. | 39,691 0.1% | -2,275,475 (-98.29%) | View |
| 2021-02-11 5:27 pm Sale | 13G | SYROS PHARMACEUTICALS INC SYRS | Nikko Asset Management Americas Inc. | 4,381,992 9.57% | -592,670 (-11.91%) | View |
| 2021-02-08 10:33 am Purchase | 13G | SYROS PHARMACEUTICALS INC SYRS | FMR LLC | 6,912,335 14.999% | 505,426 (+7.89%) | View |
| 2021-02-05 06:10 am Sale | 13G | SYROS PHARMACEUTICALS INC SYRS | Sumitomo Mitsui Trust Holdings Inc. | 4,381,992 9.57% | -592,670 (-11.91%) | View |
| 2021-02-02 5:02 pm Sale | 13G | SYROS PHARMACEUTICALS INC SYRS | ARCH Venture Fund VII L.P. | 0 0% | -3,341,770 (Position Closed) | View |
| 2021-02-01 08:23 am Purchase | 13G | SYROS PHARMACEUTICALS INC SYRS | BlackRock Inc. BLK | 3,325,560 7.3% | 462,148 (+16.14%) | View |
| 2020-12-18 4:20 pm Purchase | 13G | SYROS PHARMACEUTICALS INC SYRS | Ally Bridge MedAlpha Master Fund L.P. | 3,033,125 5.4% | 3,033,125 (New Position) | View |
| 2020-12-14 5:12 pm Purchase | 13G | SYROS PHARMACEUTICALS INC SYRS | Bain Capital Life Sciences Fund II L.P. | 5,785,036 11% | 5,785,036 (New Position) | View |
| 2020-10-09 2:16 pm Purchase | 13G | SYROS PHARMACEUTICALS INC SYRS | ARK Investment Management LLC | 11,212,506 24.5% | 6,134,699 (+120.81%) | View |